Location: United Kingdom
Their precision platform can make sense of chromosomal instability and predict the outcomes of different medications.
When it comes to deciding what medication to give cancer patients, doctors typically have two options; a standard option or precision medicine. In the standard option, two different people with the same cancer are given the same drug. In precision medicine, the treatment seeks to take into account the individual’s genetic mutations. The tailored approach means a higher likelihood of medication being a success.
However, for some cancers, this method becomes extremely complex. Cancers including the brain, lung, and ovarian cancer, have something called chromosomal instability in common. They have hundreds or thousands of mutations, making it challenging to narrow down what drugs to target what mutations. Instead, doctors have to resort to the standard approach to treatment planning – Choosing chemotherapy drugs which have had the best response on the average population. This can lead to lower response rates, unnecessary side effects, and wasted time for the patient.
Tailor Bio has developed the technology to make some sense of the genetic complexity in chromosomal instability. Their precision oncology platform uses machine learning to identify patterns in the genetic changes and then predicts the outcome of using different drugs. By analysing a sample taken from the patient’s tumour, they can provide doctors with a report of their findings for an informed treatment plan.
This approach for cancer treatment can help ensure patients get the best treatment first time, and increase the chances of a positive outcome. It also saves time and costs within healthcare systems. Cambridge cancer genomics is another company using advances in AI, genomics and big data to help patients get the right drug quicker for cancer.